Introduction: Salmonellosis, which is caused by nontyphoid salmonella bacteria, is one of the most common foodborne diseases, and it causes gastrointestinal infections worldwide, most of which are limited gastroenteritis that requires antimicrobial treatment. The aim of this study was to investigate the effects of echinophora platyloba extract on inhibiting the growth of Salmonella typhi, Salmonella enteritidis, and salmonella choleraesuis. 

Methods: Echinophora Platyloba extract was collected in the East Azarbaijan Province in Iran in June 2015. Weeds, infected plants, and dried roots were separated and removed. After drying and grinding the plant, 100 grams of powder were weighed, and the extraction of the plant was carried out by percolation. This study tested the Minimum Inhibitory Concentration (MIC) by the broth micro dilution method and Minimum Bactericidal Concentration (MBC). All of the data were analyzed by SPSS statistical software, version 22.0. One-Way ANOVA and the Duncan test were used to compare the effect of various concentrations of the extract on each type of bacteria.

Results:  Our results indicated that, in 250 mg/ml of extracts discs, the largest growth inhibition zones were formed, and they were 26.11 ± 1.16, 21.23 ± 0.89, and 19.65 ± 0.60 in S. enteritidis, S. typhi, and S. choleraesuis groups, respectively. The statistical results indicated that, in each type of bacteria, there was a statistical difference (p < 0.01) between the various concentrations of the extracts and the chloramphenicol discs. Also, it was indicated that this extract at a concentration of 150 mg/ml had a germicidal effect on S. enteritidis and S. typhi bacteria and that 250 mg/ml had a bactericidal effect on S. choleraesuis. 

Conclusion: The results of this study indicated that E. platyloba extract has potential effects as antimicrobial agents.


Keywords: antimicrobial action, echinophora platyloba, salmonella
» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/1943

Current Issue

In the second issue of the journal Electronic Physician for 2019, we have several papers including four Randomized Controlled Trials, a model development study, a case report, an editorial, a letter to editor (LTE), and several original research including two studies with qualitative approach. Authors of this issue are from nine countries: Iran, The Netherlands, Sweden, Italy, India, Thailand, Saudi Arabia, United Arab Emirates (UAE), and Jordan. Read more...


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: